

August 2020

specialty medical injectables update **bulletin**

UnitedHealthcare Specialty Medical Injectable Drug Program Updates

Provider Administered Drugs – Site of Care: Ocrevus® (Ocrelizumab)

In the [May Network Bulletin](#), we communicated that Ocrevus® (ocrelizumab) was subject to site of care requirements. However, the revised Utilization Review Guideline titled *Provider Administered Drugs – Site of Care* inadvertently failed to list Ocrevus® (ocrelizumab). We have updated the policy to list Ocrevus® (ocrelizumab) and apologize for the inconvenience.

The updated policy is available at:

- Commercial Utilization Review Guideline: [Provider Administered Drugs – Site of Care](#)
- Oxford Clinical Policy: [Provider Administered Drugs – Site of Care](#)

UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	Treatment Uses	Summary of Changes
Ocrevus®	Oct. 1, 2020		X		Ocrevus is for the treatment of multiple sclerosis.	<ul style="list-style-type: none"> • For UHC Community Plan New Jersey, New York, and Ohio – Add clinical criteria to include a step therapy requirement through rituximab for members with relapsing-remitting multiple sclerosis. • The step therapy will only apply to new users, not existing Ocrevus users.

UPDATES TO DRUG PROGRAM REQUIREMENTS AND DRUG POLICIES

Drug Name	Effective Date	UHC Commercial	UHC Community Plan	UHC Medicare Advantage	Treatment Uses	Summary of Changes
<u>Rituximab®</u>	Oct. 1, 2020	X			For the treatment of certain autoimmune diseases and types of cancer.	<ul style="list-style-type: none"> • Add clinical criteria to include a step therapy requirement through both Ruxience and Truxima, prior to the use of Rituxan or Rituxan Hycela. • Members need to step through both preferred products, Ruxience and Truxima, in order to be eligible for coverage of a non-preferred. • These updates apply to oncology and non-oncology use.

Upon prior authorization renewal, the updated policy will apply. UnitedHealthcare will honor all approved prior authorizations on file until the end date on the authorization or the date the member's eligibility changes. You don't need to submit a new notification/prior authorization request for members who already have an authorization for these medications on the effective date noted above.

Note: Certain specialty medical injectable drug program updates will not be implemented for providers practicing in Rhode Island until reviewed and approved by the Rhode Island Office of Health Insurance Commissioner (OHIC).